102,207 research outputs found
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease (Molecular Neurobiology, (2021), 58, 6, (2663-2670), 10.1007/s12035-021-02287-z)
No full textThe original version of this article unfortunately contained some mistakes. The surnames and given names of authors were interchanged. It should be: Elisabetta Signoriello, Marta Mallardo, Ersilia Nigro, Rita Polito, Sara Casertano, Andrea Di Pietro, Marcella Coletta, Maria Ludovica Monaco, Fabiana Rossi, Giacomo Lus, and Aurora Daniele The original article has been corrected
Exploitation of Brillouin spectroscopy for the characterization of a silica film
No full textMeasurement of the elastic properties of micrometric layers is important for MEMS design and manufacturing. Brillouin scattering, the scattering of light by ultrasonic waves, offers the possibility to probe the propagation of acoustic excitations of sub-micrometric wavelength, by contact-less and local measurements. From the acoustic properties the elastic ones can be derived. In the case of transparent supported films bulk waves can be measured in two different scattering geometries, together with surface acoustic waves. The smallness of the probed wavelengths allows a spatial resolution not achievable by other ultrasonic techniques. Brillouin scattering has been exploited to characterize a silica layer of micrometric thickness, thermally grown on a silicon substrate. The observation of various acoustic modes allows to derive the values of all the elastic moduli and of Poisson’s ratio of the silica film, together with its refractive index
ACUTE KIDNEY INJURY Intravenous hydration for the prevention of CIAKI
No full textIodinated contrast media are essential for diagnostic and interventional radiological and cardiological procedures, but may cause kidney damage. Intravenous hydration is the current cornerstone for prevention of contrast-induced acute kidney injury; however, new data from the AMACING trial suggest that this approach might not be beneficial in low-risk patients
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study
No full textTo investigate the effect of drug withdrawal on the course of relapsing-remitting multiple sclerosis (RR-MS)
Ketogenic diet for the treatment of catastrophic epileptic encephalopathies in childhood.
No full textThe ketogenic diet for the treatment of refractory epileptic encephalopathies has been suggested as an early treatment option in very young children. The aim of the present study was to assess the efficacy and tolerability of the ketogenic diet in children younger than 5 years, all affected by different types of catastrophic childhood encephalopathies. The study group is composed of 38 children (22 males and 16 females), aged between 3 months and 5 years, affected by symptomatic partial epilepsy (6) and cryptogenic-symptomatic epileptic encephalopathies (32). Psychomotor delay-mental retardation was present in all of the patients: mild to moderate (9), severe (7), and profound (22). Cerebral palsy was present in 74% of the cases. Children were started on a 4:1 ketogenic diet as ketocal formula alone or supporting about the 80% of the daily caloric amount. Children poorly complying with ketocal milk were shifted to a classic 4:1 ketogenic diet. The average time (months +/- S.D.) on the diet was 10.3 +/- 7.4. All the children initiating the diet remained on it at 1 month and 35 of them (92%) at 3 months, 28 (73.7%) remained on it at 6 months, and 20 (52.7%) at 1 year. At 12-month follow-up, 11 children (28.9%) had a greater than 50% reduction of seizures and the other 9 (23.7%) were seizure-free. Adverse side effects were recorded in 25 of 38 patients (65.8%), including drowsiness, constipation, weight loss, vomiting, gastroesophageal reflux, fever, and hyperlipidemia. This report confirms that severe epileptic encephalopathies are much suitable for the ketogenic diet
Long term effects of low protein diet on depressive symptoms and quality of life in elderly Type 2 diabetic patients
No full textObjectives: The long term effects of a low protein diet (LPD) on depressive symptoms and the quality of life in elderly Type 2 diabetic are unclear. Methods: 38 elderly Type 2 diabetic patients with CRD (Stage 3 – 4) were enrolled in the study. After 4 weeks on a normal protein diet regimen (NPD) providing 1.0 g/kg per day, all participants were assigned for 30 months, randomly, to a LPD (0.7 g/kg per day), either 7 days a week (LPD 7/7) or 6 days a week (LPD 6/7). Mini mental state examination (MMSE), activities daily living (ADL), cumulative illness severity (CIRS-IS), geriatric depression scale (GDS-15) and short-form healthy survey (SF- 36) were evaluated every 3 months. Results: Before the LPD regimen creatinine clearance (CrCl), MMSE, ADL, CIRS-IS, GDS-15 and SF-36 were similar in both LPD 7/7 and LPD 6/7 groups. After 30 months, the mean GDS- 15 increased significantly more in LPD 7/7 group than in LPD 6/7 group (p < 0.05). Both mean SF-36 MCS and SF-36 PCS were decreased significantly more in LPD 7/7 group than in LPD 6/7 group (p < 0.05). After 30 months, the decline in CrCl observed was similar in LPD 7/7 and LPD 6/7 groups (2.77 ± 0.3 and 2.84 ± 0.3 ml/min/year, respectively). Conclusion: In elderly Type 2 diabetic patients, long term effects of LPD 6/7 regimen in comparison to LPD 7/7 are associated with a similar decline in CrCl, but with decreased depressive symptoms and a better quality of life
Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats.
No full textDespite anticonvulsant efficacy in animal models of generalized epilepsy, levetiracetam was not
effective in the maximal subcutaneous PTZ model in mice and rats.
Aim of this study was to assess the efficacy of levetiracetam (LEV) against submaximal, s.c. MET test
(PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA).
Thirty male Wistar rats (P42) were divided in three drug-treatment groups (10 rats in each group) as
follows: valproic acid, levetiracetam, and controls. All animals were tested for seizure threshold at age
P50. VPA (110 mg/kg) and LEV (108 mg/kg) were freshly dissolved in saline and injected i.p. in 2–3 ml/kg,
15 and 30 min, respectively, before pentylenetetrazol (PTZ) injection at the dose of 70 mg/kg.
The average latency of the seizure type 3 (generalized clonic seizure with loss of righting reflexes)
significantly differed between controls and the drug-treated animal groups (p 0.02). The average
duration of the seizure type 2 (threshold seizure) was significantly longer in both groups compared to
controls (<0.02).
In conclusion, LEV plays a role against seizures triggered by subcutaneous PTZ injection given at
submaximal doses in rats, as demonstrated by a significant increase in duration of the seizure type 2
(threshold seizure)
- …
